Skip to main navigation Skip to search Skip to main content

Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease

  • University of Sheffield
  • Sheffield Teaching Hospitals NHS Foundation Trust

Research output: Contribution to journal › Review article › peer-review

11 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) often leads to mineral and bone disorders (CKD-MBDs), which are nearly universal in patients undergoing dialysis. CKD-MBD includes abnormal calcium-phosphate metabolism, vascular and soft tissue calcification, and bone abnormalities (renal osteodystrophy [ROD]). Bone fragility in CKD occurs due to low bone mass and poor bone quality, and patients with CKD have higher fracture and mortality rates. Bone histomorphometry is the gold standard for ROD diagnosis; however, it is labor-intensive and expensive. The Kidney Disease Improving Global Outcomes clinical practice guidelines on CKD-MBD suggest serum parathyroid hormone (PTH) and bone-specific alkaline phosphatase (bone ALP) for predicting bone turnover in ROD. In this review, we focus on the role of PTH and bone turnover markers, intact procollagen type N-terminal propeptide of type I collagen, bone ALP, and tartrate-resistant acid phosphatase 5b in diagnosing ROD, predicting fractures, and guiding treatment in patients with CKD.

Original languageEnglish
Pages (from-to)264-278
Number of pages15
JournalJournal of Bone Metabolism
Volume31
Issue number4
DOIs
Publication statusPublished - Nov 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Alkaline phosphatase
  • Bone diseases
  • Chronic kidney disease-mineral and bone disorder
  • Parathyroid hormone

Fingerprint

Dive into the research topics of 'Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease'. Together they form a unique fingerprint.

Cite this